Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine

Clinical Infectious Diseases

Volumn 28, Issue 5, 1999, Pages 1032-1035

  Bessesen, Mary ^a   Ives, David ^b   Condreay, Lynn ^b   Lawrence, Steven ^b   Sherman, Kenneth E ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALBUMIN; ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD4 ANTIGEN; DIDANOSINE; DIURETIC AGENT; EFAVIRENZ; HEPATITIS B SURFACE ANTIGEN; INDINAVIR; LACTULOSE; LAMIVUDINE; NELFINAVIR; PREDNISONE; STAVUDINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESISTANCE; DRUG WITHDRAWAL; HEPATITIS; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER FAILURE; MALE; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0032909198     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514750     Document Type: Article

References (25)

1. 1. Saillour F, Dabis F, Dupon M, et al. Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus in patients with HIV infection in Aquitaine. BMJ 1996;313:461-4.
2. 2. Davaro RE, Cheeseman SH, Keroack MA, Ellison RT III. The significance of isolated antibody to hepatitis B core antigen seropositivity in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23: 189-90.
3. 3. Scharschmidt BF, Held MJ, Hollander HH, et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 1992;117:837-8.
4. 4. Horvath J, Raffanti SP. Clinical aspects of the interaction between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis 1994;18:339-47.
5. 5. Mai AL, Yim C, O'Rourke K, Heathcote EJ. The interaction of human immunodeficiency virus and hepatitis B virus infection in infected homosexual men. J Clin Gastroenterol 1996; 22:299-304.
6. 6. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336:347-56.
7. 7. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348:1212-5.
8. 8. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62: 1456-62.
9. 9. Nevens F, Main J, Honkoop P, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997; 113:1258-63.
10. 10. Honkoop P, De Man RA, Zondervan PE, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997; 17:103-6.
11. 11. Bartholomew MM, Jansen RW, Jeffers J, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:20-2.
12. 12. Niesters HG, Honkoop P, Haagsma EB, De Man RA, Schalm SW, Osterhaus AD. Identification of more than one mutation in the hepatitis B virus polymerase gene during prolonged lamivudine treatment. J Infect Dis 1998; 177:1382-5.
13. 13. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DR. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8.
14. 14. Marinos G, Naoumov NV, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B infection. Hepatology 1996; 24:991-5.
15. 15. Rostaing L, Henry S, Cisterne JM, Duffaut M, Icart J, Durand D. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64:1624-7.
16. 16. Can A, Cooper DA, Restoration of immunity to chronic hepatitis B infection in an HIV-infected patient on protease inhibitor. Lancet 1997; 349: 995-6.
17. 17. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19:1409-17.
18. 18. Honkoop P, Niesters HG, De Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997; 26:1393-5.
19. 19. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338:1281-92.
20. 20. Levy P, Marcellin P, Martinot-Peignoux M, Degott C, Nataf J, Benhamou JP. Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B. Hepatology 1990; 12: 570-4.
21. 21. Schiano TD, Lissoos TW, Ahmed A, et al. Lamivudine-stavudine-induced liver failure in hepatitis B cirrhosis. Am J Gastroenterol 1997; 92: 1563-4.
22. 22. Tur-Kaspa R, Klein A, Aharonson S. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity. Hepatology 1992; 16:1338-42.
23. 23. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-45.
24. 24. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 1991; 100:182-8.
25. 25. Phillips P, Rouleau D, Montaner JS. Mycobacterial lymphadenitis: can HAART unmask subclinical infection? [abstract no 351]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, Virginia: IDSA Foundation for Retrovirology and Human Health, 1997:129.